4362 |
Optimal Indication for CEP for TAVR: Insights from the STS-TVR and PROTECTED-TAVR |
David Joel Cohen |
Apr. 20. 23 |
4361 |
TAVR Techniques in Bicuspid Anatomy – Valve Selection, Sizing, and Positioning |
Jung-Min Ahn |
Apr. 20. 23 |
4360 |
SAVR is Better |
Vinayak Bapat |
Apr. 20. 23 |
4359 |
TAVR is Better |
Eberhard Grube |
Apr. 20. 23 |
4358 |
PROTECTED-TAVR: Statistical or Clinical Interpretation and My Take-Home Messages |
Samir R. Kapadia |
Apr. 20. 23 |
4357 |
Next Innovation in Transcatheter Valve Intervention: New Techniques and New Valves |
Tullio Palmerini |
Apr. 20. 23 |
4356 |
How Recent Guidelines will Change the Practical Indication of TAVR in the Coming Years? |
Alan C. Yeung |
Apr. 20. 23 |
4355 |
The 20th Anniversary of TAVR Ceremony - From Concept to Human Application |
Alain G. Cribier |
Apr. 20. 23 |
4354 |
BRIGHT-4 Trial; Bivalirudin with a Post-PCI High-Dose Infusion vs. Heparin Monotherapy During Primary PCI in STEMI |
Gregg W. Stone |
Apr. 20. 23 |
4353 |
Updated Evidence and Recommendation of Antithrombotic Therapy after TAVR |
George D. Dangas |
Apr. 20. 23 |